Pharma
-
Courtesy of Sanofi
Sanofi halts development of troubled immune drug in eczema
The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue “strategic action” to boost its pipeline.
By Gwendolyn Wu • July 24, 2026 -
Courtesy of GSK
GSK lung cancer drug gets speedy approval following $10.6B deal
The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.
By Ben Fidler • July 22, 2026 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Getty Images
Obesity drugsNovo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “truthful.”
By Jonathan Gardner • July 21, 2026 -
Getty Images
Novartis climbs on upbeat drug sales as key readouts loom
A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
By Kristin Jensen • July 21, 2026 -
Almac Clinical Services/BioPharma Dive
Sponsored by Almac Clinical Services[Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services
This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.
By BioPharma Dive's studioID • Updated May 26, 2026 -
Getty Images
GSK shelves cough drug acquired in $2B deal
Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.
By Jonathan Gardner • July 17, 2026 -
Courtesy of Merck & Co.
Merck wins first approval of a PCSK9 cholesterol pill
The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.
By Ben Fidler • Updated July 16, 2026 -
Sarah Silbiger via Getty Images
Celcuity gains FDA approval for closely watched breast cancer drug
Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.
By Delilah Alvarado • Updated July 15, 2026 -
Permission granted by Roche
Roche scraps two Ionis-partnered Huntington’s drugs
The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.
By Jonathan Gardner • July 9, 2026 -
Getty Images
GSK ends brain drug alliance with Alector
Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.
By Jacob Bell • July 9, 2026 -
Robert Way via Getty Images
China competitionAstraZeneca, GSK intensify China ties with Sino Biopharm deals
The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions in the U.S.
By Jonathan Gardner • July 8, 2026 -
Permission granted by Novartis
Novartis to acquire ADC developer in a deal worth up to $1.5B
The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.
By Delilah Alvarado • July 6, 2026 -
Getty Images
Roche KRAS drug succeeds in head-to-head lung cancer study
The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.
By Kristin Jensen • July 2, 2026 -
Getty Images
News roundupIpsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.
By BioPharma Dive staff • June 30, 2026 -
Getty Images
Theravance, after clinical setbacks, agrees to $929M buyout
The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.
By Jonathan Gardner • June 29, 2026 -
Getty Images
News roundup
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.
By BioPharma Dive staff • June 26, 2026 -
Getty Images
On second try, Acadia drug gets nod from European regulators
The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.
By Jonathan Gardner • June 26, 2026 -
Jeenah Moon via Getty Images
Pfizer drug acquired in Seagen deal disappoints in lung cancer study
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.
By Delilah Alvarado • June 23, 2026 -
Getty Images
China competitionHHS, responding to China’s rise, moves to fast-track early drug research
A series of newly planned reforms are designed to entice companies to start early trials in the U.S. rather than overseas.
By Jonathan Gardner • June 23, 2026 -
Getty Images
Hospitals irate after Eli Lilly follows through on 340B ultimatum
The drugmaker stopped paying 340B discounts to hospitals that didn’t comply with its new paperwork requirements late last week. Hospitals are urging HRSA to step in.
By Rebecca Pifer Parduhn • June 23, 2026 -
Permission granted by Walgreens
Sponsored by WalgreensThe first 14 days: How specialty programs set patients up for success
As specialty medicines play a growing role in healthcare, the patient journey that follows is equally critical.
June 22, 2026 -
Getty Images
News roundup
Neumora depression drug fails; EnGene to cut 50% of staff
Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.
By BioPharma Dive staff • June 16, 2026 -
William Walker/BioPharma Dive
Sponsored by Pearson[Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus
This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.
By BioPharma Dive's studioID • June 16, 2026 -
Getty Images
Medicare drug price rule may target under-the-skin Keytruda and Opdivo
For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.
By Jonathan Gardner • June 15, 2026 -
Getty Images
Lilly scores early positive data for new JAK drug
Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.
By Jacob Bell • June 15, 2026
